Anti-Vimentin Nanobody Decreases Glioblastoma Cell Invasion In Vitro and In Vivo
Authors:
- Alja ZottelAZAlja Zottel
- Metka NovakMNMetka Novak
- Neja ŠamecNŠNeja Šamec
- Bernarda MajcBMBernarda Majc
- Sara ColjaSCSara Colja
- Mojca KatrašnikMKMojca Katrašnik
- Miloš VittoriMVMiloš Vittori
- Barbara HrastarBHBarbara Hrastar
- Ana RotterAna Rotter
- Andrej PorčnikAPAndrej Porčnik
- Tamara Lah TurnšekTTTamara Lah Turnšek
- Radovan KomelRKRadovan Komel
Open Access
Abstract
Purpose: Glioblastoma (GBM) is the most common primary brain tumour and one of the deadliest cancers. In addition to late diagnosis and inadequate treatment, the extremely low survival rate is also due to the lack of appropriate therapeutic biomarkers and corresponding therapeutic agents. One of the potential therapeutic biomarkers is the intermediate filament vimentin, which is associated with epithelial-mesenchymal transition (EMT). The purpose of this study was to analyse the effect of the anti-vimentin nanobody Nb79 on cell invasion in vitro and in vivo. To further our understanding of the mechanism of action, we investigated the association between Nb79 and EMT in GBM and GBM stem cells by analysing the expression levels of key EMT-related proteins. Methods: The expression of vimentin in glioma tissues and cells was determined by RT-qPCR. An invasion assay was performed on differentiated glioblastoma cell line U-87 MG and stem cell line NCH421k in vitro as well as in vivo in zebrafish embryos. The effect of Nb79 on expression of EMT biomarkers beta-catenin, vimentin, ZEB-1 and ZO1 was determined by Western blot and immunocytochemistry. Results: Our study shows that vimentin is upregulated in glioblastoma tissue compared to lower grade glioma and non-tumour brain tissue. We demonstrated that treatment with Nb79 reduced glioblastoma cell invasion by up to 64% in vitro and up to 21% in vivo. In addition, we found that the tight junction protein ZO-1 had higher expression on the cell membrane, when treated with inhibitory anti-vimentin Nb79 compared to control. Conclusion: In conclusion, our results suggest that anti-vimentin nanobody Nb79 is a promising tool to target glioblastoma cell invasion.Keywords
Funding Information
- The Slovenian Research and Innovation Agency (Z3-2649, Z3-4510, P1-0390, P1-0245, P4-0432, J3-4504, CutCancer; 101079113)
- Interreg EC Project TRANS-GLIOMA (Interreg 2014–2020 V-A It.-Slo., Ref. No. 146) (Z3-2649, Z3-4510, P1-0390, P1-0245, P4-0432, J3-4504, CutCancer; 101079113)
- HE project Twinning (Z3-2649, Z3-4510, P1-0390, P1-0245, P4-0432, J3-4504, CutCancer; 101079113)
This publication has 53 references indexed in Scilit:
- Glioblastoma and Other Malignant GliomasJAMA, 2013
- Cell‐penetrating anti‐GFAP VHH and corresponding fluorescent fusion protein VHH‐GFP spontaneously cross the blood‐brain barrier and specifically recognize astrocytes: application to brain imagingThe FASEB Journal, 2012
- The many faces and functions of β‐cateninThe EMBO Journal, 2012
- Vimentin in cancer and its potential as a molecular target for cancer therapyCellular and Molecular Life Sciences, 2011
- Integrated Genomic Analysis Identifies Clinically Relevant Subtypes of Glioblastoma Characterized by Abnormalities in PDGFRA, IDH1, EGFR, and NF1Cancer Cell, 2010
- Changes of AXIN-1 and Beta-Catenin in Neuroepithelial Brain TumorsPathology and Oncology Research, 2009
- β-Catenin and ZO-1: Shuttle Molecules Involved in Tumor Invasion-Associated Epithelial-Mesenchymal Transition ProcessesCells Tissues Organs, 2007
- Nanobodies as novel agents for cancer therapyExpert Opinion on Biological Therapy, 2005
- UniProt: the Universal Protein knowledgebaseNucleic Acids Research, 2004
- Single‐domain antibody fragments with high conformational stabilityProtein Science, 2002